Search research articles
Contact Us
Filters
Showing results (51-60 of 68) with videos related to
Page
of 7
Sort By:
Ebiomedicine
|
November 27, 2022
Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial
DeAnna J Friedman-Klabanoff, Megan Birkhold, Mara T Short, et al.
Breast Cancer Research and Treatment
|
October 23, 2014
Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples
Timothy R Wilson, Yuanyuan Xiao, Jill M Spoerke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2022
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results
Geoffrey J Lindeman, Tharu M Fernando, Rebecca Bowen, et al.
Cancer Discovery
|
March 24, 2017
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
Dejan Juric, Ian Krop, Ramesh K Ramanathan, et al.
Breast Cancer Research and Treatment
|
August 2, 2019
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer
Vandana G Abramson, Mafalda Oliveira, Andrés Cervantes, et al.
Journal of the National Cancer Institute
|
May 23, 2018
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
Michail Ignatiadis, Gert Van den Eynden, Salgado Roberto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2018
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
Maura N Dickler, Cristina Saura, Donald A Richards, et al.
Plos One
|
March 8, 2013
High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck
David S Shames, Juliet Carbon, Kim Walter, et al.
NPJ Breast Cancer
|
July 20, 2017
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population
Timothy R Wilson, Jianjun Yu, Xuyang Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2020
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers
Komal Jhaveri, Matthew T Chang, Dejan Juric, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 68) with videos related to
Sort By:
Page
of 7
Ebiomedicine
|
November 27, 2022
Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial
DeAnna J Friedman-Klabanoff, Megan Birkhold, Mara T Short, et al.
Breast Cancer Research and Treatment
|
October 23, 2014
Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples
Timothy R Wilson, Yuanyuan Xiao, Jill M Spoerke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2022
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results
Geoffrey J Lindeman, Tharu M Fernando, Rebecca Bowen, et al.
Cancer Discovery
|
March 24, 2017
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
Dejan Juric, Ian Krop, Ramesh K Ramanathan, et al.
Breast Cancer Research and Treatment
|
August 2, 2019
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer
Vandana G Abramson, Mafalda Oliveira, Andrés Cervantes, et al.
Journal of the National Cancer Institute
|
May 23, 2018
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
Michail Ignatiadis, Gert Van den Eynden, Salgado Roberto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2018
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
Maura N Dickler, Cristina Saura, Donald A Richards, et al.
Plos One
|
March 8, 2013
High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck
David S Shames, Juliet Carbon, Kim Walter, et al.
NPJ Breast Cancer
|
July 20, 2017
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population
Timothy R Wilson, Jianjun Yu, Xuyang Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2020
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers
Komal Jhaveri, Matthew T Chang, Dejan Juric, et al.
Page
of 7